{"meshTagsMajor":["Immunotherapy"],"meshTags":["Humans","Immunotherapy","Melanoma","Protein Kinase Inhibitors","Proto-Oncogene Proteins B-raf"],"meshMinor":["Humans","Melanoma","Protein Kinase Inhibitors","Proto-Oncogene Proteins B-raf"],"genes":["BRAF"],"publicationTypes":["Comment","Editorial","Research Support, Non-U.S. Gov\u0027t"],"title":"Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma.","pubmedId":"24577788"}